New Approaches to the Surgical Treatment for Radical Cystectomy in Bladder Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 136
Special Issue Editors
Interests: prostate cancer; bladder cancer; renal cell carcinoma; robot-assited surgery
Interests: prostate cancer; bladder cancer; renal cell carcinoma; robot-assited surgery
Special Issue Information
Dear Colleagues,
It is noteworthy that radical cystectomy still represents the cornerstone for treatment of bladder cancer. However, over the last few decades, changes in patient and tumor characteristics, as well as technological innovations, have contributed to important advancements in the surgical treatment of bladder cancer.
First, radical cystectomy is nowadays more frequently delivered in patients with less aggressive tumor characteristics. Indeed, radical cystectomy is the preferred option in patients diagnosed with BCG failure and very-high risk non-muscle invasive bladder cancer. Moreover, neoadjuvant chemotherapy for muscle-invasive bladder cancer has increased the proportion of patients with no residual disease at final pathology. Second, attention to quality of life across all ages has encouraged urologists to propose orthotopic neobladder, develop sex-sparing techniques and limit pelvic lymph node dissection template whenever possible. Third, the popularity of robotic surgery has led urologists and healthcare systems to support the introduction of robot-assisted radical cystectomy in everyday clinical practice while creating a strong linkage between technical and surgical innovations. Taken together, we believe that radical cystectomy represents an evolving landscape. In consequence, the objective of the current Special Issue is to collect updated evidences of new approaches for surgical treatment of bladder cancer.
We look forward to receiving your contributions.
Dr. Costantino Leonardo
Dr. Flavia Proietti
Dr. Rocco Simone Flammia
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- bladder cancer
- neoadjuvant chemotherapy
- pelvic lymph node dissection
- robot-assisted radical cystectomy
- BCG failure
- sex-sparing
